Charles Jeffrey Smith

Title: Innovations by Charles Jeffrey Smith in Cancer Diagnosis and Treatment

Introduction

Charles Jeffrey Smith is an accomplished inventor based in Columbia, MO (US). He has made significant contributions to the field of cancer diagnosis and treatment, holding a total of 2 patents. His work focuses on developing innovative solutions that target specific receptors involved in prostate cancer.

Latest Patents

Smith's latest patents include groundbreaking inventions aimed at improving cancer diagnosis and treatment. One of his notable patents is the "Dual targeting ligand for cancer diagnosis and treatment." This invention discloses compositions and methods related to prostate cancer, specifically bivalent targeting ligands that bind to prostate-specific membrane antigen and gastrin-releasing peptide receptor. These bivalent binding agents can be utilized to image tissue in subjects and diagnose prostate cancer effectively. Furthermore, they can also be employed in the treatment of prostate cancer.

Another significant patent is the "Gastrin receptor-avid peptide conjugates." This compound serves as a therapeutic or diagnostic radiopharmaceutical, featuring a group capable of complexing a medically useful metal attached to a moiety that binds to a gastrin-releasing peptide receptor. The method for treating neoplastic diseases involves administering an effective amount of a radiopharmaceutical that has a metal chelated with a chelating group, which is linked to a moiety capable of binding to the gastrin-releasing peptide receptor expressed on tumor cells.

Career Highlights

Charles Jeffrey Smith is affiliated with the University of Missouri, where he continues to advance his research and innovations in cancer treatment. His work has garnered attention for its potential to improve patient outcomes in oncology.

Collaborations

Smith has collaborated with notable colleagues, including Timothy J. Hoffman and Wynn A. Volkert, contributing to the advancement of cancer research and therapeutic methods.

Conclusion

Charles Jeffrey Smith's innovative work in cancer diagnosis and treatment exemplifies the impact of targeted therapies in modern medicine. His patents reflect a commitment to improving the lives of patients facing prostate cancer.